trial

CATIE- Schizophrenia Trial

NCTId NCT00014001
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 1,600
Sponsored by National Institute of Mental Health (NIMH)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
1,600
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2000-12
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ZiprasidoneClozapinePerphenazineOlanzapineQuetiapineRisperidoneFluphenazine

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Jeffrey A. Lieberman, MDStudy Director

Sites

54 total
Chula Vista, United StatesLos Angeles, United StatesOrange, United StatesSan Diego, United StatesStanford, United StatesTorrance, United StatesNew Britain, United StatesNew Haven, United StatesBoca Raton, United StatesMiami, United StatesMiami, United StatesAtlanta, United States

Facts & assertions

3 sourced
Enrollment
1,600
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
Clozapine
drug
Perphenazine
drug
Olanzapine
drug
Quetiapine
drug
Risperidone
drug
Fluphenazine
drug
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jeffrey A. Lieberman, MD
person